Vincristine (Pediatric)
A vinca alkaloid that stops cell division. **Warning: For Intravenous use ONLY. Intrathecal administration is fatal.**
Dosage by Body Weight
Pediatric dose: 1.5 mg/m² (for weight >10kg) or 0.05 mg/kg (for weight <10kg). Max dose 2 mg.
- Body Weight
- Below 10 kg
- Dose
- 0.05 mg per kg
- Frequency
- Weekly (Oncology schedule)
- Tracking Notes
- Monitor for constipation and peripheral neuropathy (weakness).
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 10 kg | 0.05 mg per kg | Weekly (Oncology schedule) | Monitor for constipation and peripheral neuropathy (weakness). |
Formulation
Purpose
Chemotherapy for pediatric cancers including Acute Lymphoblastic Leukemia (ALL) and Wilms tumor.
Generic Name
Vincristine SulfateBranded Drug Names
Vincristine (Pediatric) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.
Alternatives
Safety Advice
Alcohol
CAUTIONVincristine (Pediatric): Alcohol can increase liver strain, stomach irritation, or immune-related complications. Avoid alcohol unless your specialist allows it.
Pregnancy
CAUTIONVincristine (Pediatric): Use in pregnancy only under specialist advice because immune, cancer, or transplant treatment requires careful risk assessment.
Breast Feeding
CAUTIONVincristine (Pediatric): Breastfeeding may not be recommended with some immunosuppressive or chemotherapy medicines. Follow specialist advice.
Driving
CAUTIONVincristine (Pediatric): May cause dizziness, fatigue, nausea, or weakness. Avoid driving if affected.
Liver
CAUTIONVincristine (Pediatric): Can affect liver function and usually requires regular blood tests. Use only with specialist monitoring.
Kidney
CAUTIONVincristine (Pediatric): Kidney function may need close monitoring, particularly with calcineurin inhibitors or high-risk regimens.